Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone

Anti-Cancer Drugs

Volumn 24, Issue 5, 2013, Pages 431-440

  Vrdoljak, Eduard ^a   Rini, Brian ^b   Schmidinger, Manuela ^c   Omrčen, Tomislav ^a   Torday, Laszlo ^d   Szczylik, Cezary ^e   Sella, Avishay ^f  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF SZEGED   (Hungary)

^e MILITARY INSTITUTE OF MEDICINE   (Poland)

^f ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

bevacizumab; bone metastases; pazopanib; renal cell carcinoma; sorafenib; sunitinib; zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA2A INTERFERON; AXITINIB; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; DOXORUBICIN; EVEROLIMUS; GERANYLTRANSFERASE; IBANDRONIC ACID; ISOPENTENYL DIPHOSPHATE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAMIDRONIC ACID; PAZOPANIB; SORAFENIB; SUNITINIB; TEMISOROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; BONE METASTASIS; BREAST METASTASIS; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TOXICITY; DRUG WITHDRAWAL; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY METASTASIS; LOG RANK TEST; MORBIDITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; REVIEW; SIDE EFFECT; STEREOTACTIC RADIOSURGERY; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INDOLES; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875847861     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328360335f     Document Type: Review

References (117)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, et al. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD: National Cancer Institute 2002; Available at: http://seer.cancer.gov/csr/1973-1999/.
2. Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5):v137-v139.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer 2010; Available at: http://globocan.iarc.fr [Accessed 28 January 2011].
4. Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001; 19:379-382.
5. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996; 335:865-875.
6. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-2490. (Pubitemid 41770167)
7. Lonser RR, Glenn GM,Walther M, Chew EY, Libutti SK, Linehan WM, et al. Von Hippel-Lindau disease. Lancet 2003; 361:2059-2067. (Pubitemid 36695052)
8. Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Moore AT, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77:1151-1163. (Pubitemid 20379533)
9. Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998; 12:417-423. (Pubitemid 28512618)
10. Prowse A, Webster A, Richards F, Richard S, Olschwang S, Resche F, et al. Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 1997; 60:765-771. (Pubitemid 27146484)
11. Lubensky IA, Gnarra JR, Bertheau P,Walther MM, Linehan WM, Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 1996; 149:2089-2094. (Pubitemid 26415225)
12. Gnarra JR, Tory K,Weng Y, Schmidt L,Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:85-90. (Pubitemid 24232386)
13. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994; 54:2852-2855.
14. Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002; 34:58-68. (Pubitemid 34260597)
15. Brauch H,Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000; 60:1942-1948. (Pubitemid 30207656)
16. Kenck C,Wilhelm M, Bugert P, Staehler G, Kovacs G. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 1996; 179:157-161. (Pubitemid 26201583)
17. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995; 269:1444-1446.
18. Maxwell PH,Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-275. (Pubitemid 29246458)
19. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275: 25733-25741.
20. Wang GL, Semenza GL. Purification and characterization of hypoxiainducible factor 1. J Biol Chem 1995; 270:1230-1237.
21. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996; 93:10595-10599. (Pubitemid 26333032)
22. Gnarra JR, Zhou S, Merrill MJ,Wagner JR, Krumm A, Papavassiliou E, et al. Posttranscriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996; 93:10589-10594. (Pubitemid 26333031)
23. Kourembanas S, Hannan RL, Faller DV. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J Clin Invest 1990; 86:670-674. (Pubitemid 20271905)
24. Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky DJ, et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 1995; 92:4606-4610.
25. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90:4304-4308. (Pubitemid 23134215)
26. Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K, Parolin DA, et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(- /-) renal cell carcinoma cells. J Biol Chem 2003; 278:44966-44974. (Pubitemid 37377256)
27. De Paulsen N, Brychzy A, Fournier MC, Klausner RD, Gnarra JR, Pause A, et al. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(- /-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001; 98:1387-1392. (Pubitemid 32165508)
28. Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM. Overproduction of vascular endothelial growth factor related to von Hippel- Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 2003; 170:588-592. (Pubitemid 36870265)
29. Paradis V, Lagha NB, Zeimoura L, Blanchet P, Eschwege P, Ba N, et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 2000; 436:351-356. (Pubitemid 30219233)
30. Song KH, Song J, Jeong GB, Kim JM, Jung SH, Song J. Vascular endothelial growth factor - its relation to neovascularization and their significance as prognostic factors in renal cell carcinoma. Yonsei Med J 2001; 42:539-546. (Pubitemid 33064820)
31. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PFA, Patard JJ, et al. Guidelines on renal cell carcinoma (2009). European Association of Urology. Available at: http://www.uroweb.org/fileadmin/tx-eauguidelines/2009/ Full/RCC.pdf [Accessed 14 October 2009].
32. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: kidney cancer v.2.2010. Available at: http://www.nccn.org/ professionals/physician-gls/pdf/kidney.pdf [Accessed 14 October 2009].
33. Rini BI, Small EJ. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006; 24:5601-5608.
34. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Phase III randomized trial of sunitinib malate (SU 11248) versus interferon-alfa (IFN - A) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24 (Suppl):LBA3.
35. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370:2103-2111. (Pubitemid 350296300)
36. Escudier B, Bellmunt J, Né grier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28:2144-2150.
37. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26:5422-5428.
38. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28:2137-2143.
39. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-1068.
40. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103:253-262.
41. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23:3151-3171. (Pubitemid 38638827)
42. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22:7004-7014.
43. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8:249-258. (Pubitemid 32947647)
44. Harding MW. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 2003; 9:2882-2886. (Pubitemid 36993244)
45. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-1945. (Pubitemid 39071573)
46. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12:122-127. (Pubitemid 43050086)
47. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006; 66:5549-5554. (Pubitemid 43927103)
48. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281. (Pubitemid 46849157)
49. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92:1855-1861. (Pubitemid 40826133)
50. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11:5472-5480. (Pubitemid 41060823)
51. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16:1688-1694. (Pubitemid 41510145)
52. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-972. (Pubitemid 46202316)
53. Wilhelm SM, Carter C, Tang L,Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109. (Pubitemid 39331023)
54. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:1280-1289, Erratum in: J Clin Oncol 2009; 27:2305.
55. Motzer RJ, Molina AM. Targeting renal cell carcinoma. J Clin Oncol 2009; 27:3274-3276.
56. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-2512. (Pubitemid 46630627)
57. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134, Erratum in: N Engl J Med 2007; 357:203. (Pubitemid 46089673)
58. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27:3312-3318.
59. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116:4256-4265.
60. Rini BI, Escudier B, Tomzcak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectivnes of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase III trial. Lancet 2011; 378:1931-1939.
61. Chow E, Finkelstein JA, Coleman RE. Metastatic cancer to the bone. In: DeVitta VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2008. pp. 2510-2522.
62. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9:14-27. (Pubitemid 39363165)
63. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castrationresistant prostate cancer: results of a phase 3, randomised, placebocontrolled trial. Lancet 2012; 379:39-46.
64. Chow E,Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH. International consensus on palliative radiotherapy end points for future clinical trials in bone metastases. Radiother Oncol 2002; 64:275-280. (Pubitemid 35254020)
65. Wu JSY,Wong R, Johnston M, Bezjak A,Whelan T. Meta-analysis of dosefractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55:594-605. (Pubitemid 36170000)
66. Jung ST, Ghert MA, Harrelson JM, Scully SP. Treatment of osseous metastases in patient with renal cell carcinoma. Clin Orthop 2003; 409:223-231. (Pubitemid 36417733)
67. Jhaveri P, Teh BS, Bloch C, Amato R, Butler EB, Paulino AC. Stereotactic body radiotherapy in the management of painful bone metastases. Oncology (Williston Park) 2008; 22:782-788. (Pubitemid 352007338)
68. Rohde D, Albers C, Mahnken A, Tacke J. Regional thermoablation of local or metastatic renal cell carcinoma. Oncol Rep 2003; 10:753-757.
69. Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2010; 22:794-800.
70. Patil S, Figlin RA, Hutson TE, Michaelson MD, Né grier S, Kim ST, et al. Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC) [abstract 5042]. J Clin Oncol 2009; 27:15s.
71. Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, et al. Sorafenib for metastatic renal cancer: the Princess Margaret Experience. Am J Clin Oncol 2008; 31:182-187. (Pubitemid 351519171)
72. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-593. (Pubitemid 37328925)
73. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 1:59-65. (Pubitemid 23059975)
74. Berenson JR, Lichenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-493. (Pubitemid 26067736)
75. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23:3314-3321.
76. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008; 100:1167-1178.
77. Normanno N, Gallo M, Lamura L, De Luca A. Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment [abstract 10602]. J Clin Oncol 2010; 28 (Suppl):74s.
78. Lin AY, Park JW, Scott J, Melisko M, Goga A, Moasser MM, et al. Zoledronic acid as adjuvant therapy for woman with early stage breast cancer and disseminated tumor cells in bone marrow [abstract 559]. J Clin Oncol 2008; 26 (Suppl):20s.
79. Solomayer EF, Gebauer G, Hirnle P, Janni W, Luck HJ, Becker S, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [abstract 2048]. Presented at 31st Annual San Antonio Breast Cancer Symposium; 10-14 December 2008; San Antonio, Texas.
80. Aft R, Naughton M, Trinkaus K,Watson M, Ylagan L, Chavez-MacGregor M, et al. Effect of zoledonic acid on disseminated tumour cells in woman with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010; 11:421-428.
81. Rack B, Juckstock J, Genss EM, Schoberth A, Schindlbeck C, Strobl B, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010; 30:1807-1813.
82. Ullen A, Schwarz S, Lennartsson L, Kalkner KM, Sandstrom P, Costa F, et al. Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol 2009; 43:98-103.
83. Fujita M, Tohi M, Sawada K, Yamamoto Y, Nakamura T, Yagami T, et al. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells. Oncol Rep 2012; 27:1371-1376.
84. Pandha H, Birchall L, Meyer B, Wilson N, Relph K, Anderson C, et al. Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J Urol 2006; 176:2255-2261. (Pubitemid 44633143)
85. Zwolak P, Manivel JC, Jasinski P, Kirstein MN, Dudek AZ, Fisher J, et al. Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am 2010; 92:162-168.
86. Kijima T, Fujii Y, Suyama T, Okubo Y, Yamamoto S, Masuda H, et al. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 2009; 103:620-624.
87. Takeda N, Isu K, Hiraga H, Shinohara N, Minami A, Kamata H. Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up. J Orthop Sci 2012; 17:770-774.
88. Miwa S, Mizokami A, Konaka H, Izumi K, Nohara T, Namiki M. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy. Jpn J Clin Oncol 2009; 39:745-750.
89. Kijima T, Fujii Y, Suyama T, Okubo Y, Yonese J, Fukui I. Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. Int J Urol 2008; 15:546-547. (Pubitemid 351713191)
90. Matthew RS. Antitumor activity of bisphosphonates. Clin Cancer Res 2003; 9:5433.
91. Rosen LS, Gordon D, Tschekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003; 21:3150-3157. (Pubitemid 46606297)
92. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 2004; 10:6397-6403.
93. Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A, et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone 2011; 48:160-166.
94. Yasuda Y, Fujii Y, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, et al. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. Int J Clin Oncol 2012 [Epub ahead of print].
95. Henk H, Teitelbaum A, Kaura S. Evaluation of the clinical benefit of longterm (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid. Curr Med Res Opin 2012; 28:1119-1127.
96. Yuasa T, Urakami S, Yamamoto S, Yonese J, Saito K, Takahashi S, et al. Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clin Exp Metastasis 2011; 28:405-411.
97. Keizman D, Shalom MI, Taksey JD, Pili R, Hammers HJ, Eisenberger MA, et al. Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2012; 30 (Suppl 5):379.
98. Beuselinck B,Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al. Concomitant oral tyrosine kinase inhibitors and bisposphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 2012; 107:1665-1671.
99. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, et al. In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009; 58:31-38.
100. Lang JM, Kaikobad MR,Wallace M, Staab MJ, Horvath DL,Wilding G, et al. Pilot trial of interleukin-2 and zoledronic acid to augment gd T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother 2011; 60:1447-1460.
101. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13:4482-4486. (Pubitemid 47219717)
102. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349:1676-1679, discussion 1676-1679.
103. Bujanda DA, Sarmiento UB, Cabrera Suarez MA, Morales AJ. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 2007; 18:556-560. (Pubitemid 46359639)
104. Zometa SmPC. Available at: http://www.emea.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000336/WC500051730.pdf [Accessed 9 December 2012].
105. Ibrahim A, Scher N,Williams G, Sridhara R, Li N, Chen G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003; 9:2394-2399. (Pubitemid 36842077)
106. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10:757-763.
107. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 2010; 16:4853-4863.
108. Lipton A. Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 2008; 34:25-30.
109. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76:209-211.
110. Bozas G, Allgar V, Greenwood G, Maraveyas A. Osteonecrosis of the jaw in patients treated with sunitinib and zoledronic acid [abstract]. J Clin Oncol 2011; 29:e15116.
111. Assouline DY, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002; 32:94-124. (Pubitemid 35351246)
112. Marx RE. Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115-1117. (Pubitemid 37064711)
113. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353:99-102.
114. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23:8580-8587. (Pubitemid 46211499)
115. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91:968-971. (Pubitemid 44023154)
116. Singhal S, Kut V, Tariman J. Pamidronate and zoledronate-associated osteonecrosis in myeloma is an increasing and under-recognized problem. Haematologica 2005; 90:191.
117. Tarasoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003; 61: 1238-1239. (Pubitemid 37193509)